Boston Scientific Q3 Earnings Preview - Forbes

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates. The ... Read More

Boston Scientific (BSX) Q3 Earnings Preview: What You Should Know ...

Get a deeper insight into the potential performance of Boston Scientific (BSX) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the ... Read More

Boston Scientific Q3 2020 Earnings Preview - Seeking Alpha

Boston Scientific Q3 2020 Earnings Preview Oct. 27, 2020 1:27 PM ET Boston Scientific Corporation (BSX) Stock BSX By: Meghavi Singh, SA News Editor ... Read More

Boston Scientific earnings preview: what to expect

Boston Scientific will be reporting Q1 earnings on April 28. 26 analysts expect earnings of $0.305 per share as opposed to earnings of $0.280 per share in the same quarter of the previous year. Read More

Semler Scientific Q3 2023 Earnings Preview - Seeking Alpha

Semler Scientific (SMLR) is scheduled to announce Q3 earnings results on Thursday, November 9th, after market close.\\ The consensus EPS Estimate is $0.51 and th ... Read More

Boston Scientific Q3 Earnings: Revenue And EPS Beat, Lifts Annual ...

Boston Scientific estimates 2024 adjusted EPS of $2.45-$2.47, compared to prior guidance of $2.38-$2.42 and the consensus of $2.41. Read More

Boston Scientific’s stock climbs on Q3 sales and earnings beat

Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products company reported better-than-expected profit and sales in its third-quarter results, and gave ... Read More

Earnings Preview: What To Expect from Boston Scientific's Report

With Boston Scientific gearing up to release its third-quarter earnings later this month, analysts expect double-digit earnings growth. Read More

Boston Scientific Q3 Earnings: Revenue And EPS Beat, Lifts Annual ...

Boston Scientific exceeded Q3 expectations with $4.21 billion revenue and $0.63 EPS. Cardiovascular sales rose 25%, and 2024 growth guidance was updated. Read More

Boston Scientific's stock climbs on Q3 sales and earnings beat

Related: Boston Scientific's stock jumps 3% after earnings beat and upbeat guidance The company expects net sales growth for the full year 2024 to be approximately 16.5% on a reported basis and 15 ... Read More